Petros Pharmaceuticals

Equities

PTPI

US71678J2096

Real-time Estimate Cboe BZX Other stock markets 11:53:17 23/05/2024 pm IST			5-day change	1st Jan Change
0.617 ^USD	-5.12%		+14.65%	-55.43%

14/05	Sector Update: Health Care Stocks Rise in Late Afternoon Trading	MT
14/05	Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading	MT

Petros Pharmaceuticals, Inc. Appoints Mitchell Arnold to Serve as the Principal Financial Officer and Principal Accounting Officer

January 26, 2021 at 03:41 am IST

On January 19, 2021, effective immediately, the Board of Directors of Petros Pharmaceuticals, Inc. appointed Mitchell Arnold to serve as the principal financial officer and principal accounting officer of the Company. Mr. Arnold, age 57, has served as Vice President of Finance of the Company since 2019.

Latest news about Petros Pharmaceuticals

Sector Update: Health Care Stocks Rise in Late Afternoon Trading	15/05	MT
Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading	14/05	MT
23andMe Unit Offers Petros Pharmaceuticals' Impotency Medication	14/05	MT
Lemonaid Health, Inc. Offers Prescription ED Medication STENDRA Through Collaboration with Petros Pharmaceuticals	14/05	CI
Petros, Lemonaid Health Collaborate to Expand Stendra Availability	23/04	MT
Petros Pharmaceuticals, Inc. Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health	23/04	CI
Petros Gets 'Positive' FDA Response Over Technology Component in Stendra OTC Process	16/04	MT
Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R)	16/04	CI
Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA as it Pursues OTC Status	02/04	CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
Petros Pharmaceuticals Enters into Ai Licensing Agreement with Leading Multi-Billion-Dollar Software Provider	14/02	CI
Top Premarket Gainers	30/01	MT
Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study	17/01	CI
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) the First Erectile Dysfunction Medication to Achieve OTC Status	12/12	CI
Maxim Initiates Petros Pharma at Buy Rating With $4 Price Target	08/12	MT
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug Crestor's (Rosuvastatin) OTC Switch Technology Provider	05/12	CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/11	CI
Petros Pharmaceuticals Announces to Develop Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)	30/23/30	CI
Petros Pharmaceuticals, Inc. Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA	19/23/19	CI
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential Otc Stendra Label	04/23/04	CI
Top Premarket Decliners	04/23/04	MT
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Petros Pharmaceuticals Secures $15 Million Private Placement Financing	14/23/14	MT
Petros Pharmaceuticals, Inc. announced that it has received $15 million in funding	13/23/13	CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI

Chart Petros Pharmaceuticals

Duration

Period

More charts

Company Profile

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics with a range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The Company is also focused on identifying, developing, acquiring, and commercializing therapeutics for men's health issues, including, erectile dysfunction (ED), endothelial dysfunction, psychosexual and psychosocial ailments, peyronie's disease, hormone health, and substance use disorders. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products, the Company is focused on identifying and developing other pharmaceuticals to advance men's health, which is H100, which is the topical formulation candidate for the treatment of acute peyronie's disease.

Sector

More about the company